Indantadol (CHF-3381, V-3381) is a
drug
A drug is any chemical substance that causes a change in an organism's physiology or psychology when consumed. Drugs are typically distinguished from food and substances that provide nutritional support. Consumption of drugs can be via insuffla ...
which was formerly being investigated as an
anticonvulsant
Anticonvulsants (also known as antiepileptic drugs or recently as antiseizure drugs) are a diverse group of pharmacological agents used in the treatment of epileptic seizures. Anticonvulsants are also increasingly being used in the treatment of b ...
and
neuroprotective and is now under development for the treatment of
neuropathic pain and
chronic cough in
Europe by
Vernalis and
Chiesi.
It acts as a
competitive,
reversible, and non-
selective monoamine oxidase inhibitor
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They are best known as effective antidepressants, espe ...
,
and as a low
affinity
Affinity may refer to:
Commerce, finance and law
* Affinity (law), kinship by marriage
* Affinity analysis, a market research and business management technique
* Affinity Credit Union, a Saskatchewan-based credit union
* Affinity Equity Partn ...
,
non-competitive NMDA receptor antagonist.
A
pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in
phase IIb
The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases ...
clinical trials.
See also
*
2-Aminoindane
*
Glycine
References
{{Monoamine metabolism modulators
Analgesics
Anticonvulsants
Antitussives
Monoamine oxidase inhibitors
NMDA receptor antagonists
2-Aminoindanes
Acetamides